Maxwell Biomedical Acquires Cardialen’s Assets

Cardialen, a Minneapolis, MN based company, developed MultiPulse™ Therapy (MPT™), a low-energy defibrillation and cardioversion therapy designed to treat atrial fibrillation (AFib) and ventricular tachycardias (VT). The Cardialen technology complements Maxwell’s proprietary Spatial Resynchronization™ Therapy (SR™T). Both technologies are designed to deliver critically timed ultra-low-energy pulses to restore abnormally rapid heart rates to a normal rhythm. Cardialen’s technology in combination with findings from their previous clinical studies, broadens Maxwell Biomedical’s intellectual property portfolio and expands the company’s freedom to operate.